References
- Bloom BR, Murray CJL. Tuberculosis: commentary on a re-emergent killer. Science 1992; 257: 1055
- Barnes PF, Blotch AB, Davidson PT, Snider DE, Jr. Tuberculosis in patients with immuno-deficiency virus infection. N Engl J Med 1991; 324: 1644
- Sbarbaro JA. Multidrug-resistant tuberculosis. It is time to focus on the private sector of medicine. Chest 1997; 111: 1149
- Fujiwara PI, Cook SV, Rutherford CM, Crawford JT, Glickman SE, Kreiswirth BN, Sachdev PS, Osahan SS, Ebrahimzadeh A, Frieden TR. A continuing survey of drug-resistant tuberculosis. Arch Intern Med 1997; 157: 531
- Schaberg T, Gloger G, Reichert B, Mauch H, Lode H. Resistant lung tuberculosis in Berlin 1987–1993. Pneumologie 1996; 50: 21
- Kucukguzel SG, Rollas S. Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. Farmaco 2002; 57: 583
- Shaharyar M, Siddiqui AA, Ali MA, Sriram D, Yogeeswari P. Synthesis and in vitro antimycobacterial activity of N(1)-nicotinoyl-3-(4′-hydroxy-3′-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 2006; 16: 3947–3949
- Nauduri D, Reddy GB. Antibacterials and antimycotics: Part 1: Synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull (Tokyo) 1998; 46(8)1254–1260
- Santilli AA, Kim DH, Gregory FJ. Antitubercular activity of substituted 5-oxo-1-thiocarbamoyl-3-pyrazoline-4-alkanoic acid derivatives. J Pharm Sci. 1975; 64(6)1057–1058
- Collins L, Frazblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium Antimicrob. Agents Chemother 1997; 41: 1004
- Gundersen LL, Nissen-Meyer J, Spilsberg B. Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 2002; 45: 1383